Greenland Mines Ltd. (NASDAQ: GRML) announced that Innovation, Science and Economic Development Canada has granted a patent covering technology exclusively licensed by the company for Klotho-based gene therapies targeting cognition, memory and neurodegenerative diseases. The patent protects the use of the secreted Klotho ("s-KL") RNA splice variant in genetic therapies and includes 42 claims covering its synthesis, delivery methods and potential application across multiple neurological disorders, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis ("ALS") and multiple sclerosis.
The company said the Canadian patent expands its intellectual property portfolio for Klotho-based therapeutics and complements previously issued patents in the United States, China and Europe. Greenland Mines added that process development and manufacturing for lead candidate KLTO-101 is scheduled to begin in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year.
This patent is significant because it strengthens Greenland Mines' position in the biotech sector, particularly for gene therapies aimed at devastating neurodegenerative conditions with few effective treatments. The broad scope of claims covering synthesis and delivery methods could provide a competitive advantage in developing therapies for diseases that affect millions worldwide. The company's dual focus on mining and biotech aims to build a multi-asset platform, as described on its website.
The advancement of KLTO-202 to GMP manufacturing marks a critical step toward clinical trials, potentially bringing a new treatment option for ALS patients. ALS, a progressive neurodegenerative disease, currently has limited therapeutic options, and Klotho gene therapy could address underlying mechanisms. The company's strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
For more details on the patent announcement, visit the full press release. The latest news and updates relating to GRML are available in the company's newsroom at https://ibn.fm/GRML.
